Literature DB >> 11096752

Huntington's Disease.

.   

Abstract

Huntington's disease is a neurodegenerative disorder inherited in an autosomal dominant fashion that results in involuntary movements, psychiatric symptoms, and cognitive dysfunction. The illness typically begins in midlife and progresses over 15 to 20 years, producing increasing disability. The diagnosis of Huntington's disease in an individual has implications for family members as well, whose at-risk status may be altered by the diagnosis. Genetic counseling and information about alternative approaches (eg, clinical diagnosis, DNA banking) should be provided and consent obtained before DNA testing in a symptomatic patient. Genetic counseling is essential for predictive testing in asymptomatic at-risk individuals. Although disease-modifying therapy is not yet available, a multidisciplinary approach to both pharmacologic and nonpharmacologic management can improve the motor and psychiatric symptoms of the illness and enhance function and quality of life for patients and their families. There have been few rigorous trials of treatments for Huntington's disease. The medications discussed in this article have been empirically found to be useful in the management of specific symptoms. Therapy for the movement disorder should focus on those symptoms that specifically limit function. The potential contribution of medication side effects to disability should be periodically reassessed and therapy adjusted as the disease progresses. Psychiatric symptoms are a substantial source of morbidity in this disorder and should be actively treated because they are often quite responsive to appropriate therapy. Both the motor and the psychiatric symptoms can be modified by environmental as well as pharmacologic strategies. Ongoing assessment of the need for adjunctive therapies by means of physical, occupational, and speech therapy is an important component of management, and social work intervention is often necessary to assist with the practical difficulties faced by patients and caregivers. Voluntary organizations are an important source of information and support for professionals caring for patients with Huntington's disease as well as for patients and their families.

Entities:  

Year:  2000        PMID: 11096752     DOI: 10.1007/s11940-000-0007-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  51 in total

1.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 2.  The emerging role of clozapine in the treatment of movement disorders.

Authors:  S A Factor; J H Friedman
Journal:  Mov Disord       Date:  1997-07       Impact factor: 10.338

3.  A controlled trial of remacemide hydrochloride in Huntington's disease.

Authors:  K Kieburtz; A Feigin; M McDermott; P Como; D Abwender; C Zimmerman; C Hickey; C Orme; K Claude; J Sotack; J T Greenamyre; C Dunn; I Shoulson
Journal:  Mov Disord       Date:  1996-05       Impact factor: 10.338

4.  Body weight and dietary factors in Huntington's disease patients compared with matched controls.

Authors:  P R Sanberg; H C Fibiger; R F Mark
Journal:  Med J Aust       Date:  1981-04-18       Impact factor: 7.738

Review 5.  The relationship of pharmacology to side effects.

Authors:  D E Casey
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

Review 6.  Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature.

Authors:  I Leroi; M Michalon
Journal:  Can J Psychiatry       Date:  1998-11       Impact factor: 4.356

7.  Increased rate of suicide among patients with Huntington's disease.

Authors:  M Schoenfeld; R H Myers; L A Cupples; B Berkman; D S Sax; E Clark
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-12       Impact factor: 10.154

Review 8.  Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD).

Authors:  N Quinn; R Brown; D Craufurd; S Goldman; J Hodges; K Kieburtz; O Lindvall; J MacMillan; R Roos
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

Review 9.  The neurogenetics genie: testing for the Huntington's disease mutation.

Authors:  S Hersch; R Jones; W Koroshetz; K Quaid
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

10.  Levodopa responsive parkinsonism in an adult with Huntington's disease.

Authors:  B A Racette; J S Perlmutter
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

View more
  4 in total

Review 1.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

2.  Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice.

Authors:  Fanny Mochel; Brandon Durant; Alexandra Durr; Raphael Schiffmann
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

3.  Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).

Authors:  Annie Hawton; Colin Green; Elizabeth Goodwin; Timothy Harrower
Journal:  Eur J Health Econ       Date:  2019-08-13

4.  Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.

Authors:  Jane Y Chen; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  Front Neurosci       Date:  2013-07-04       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.